177 related articles for article (PubMed ID: 34691078)
1. Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants.
Bayarri-Olmos R; Jarlhelt I; Johnsen LB; Hansen CB; Helgstrand C; Rose Bjelke J; Matthiesen F; Nielsen SD; Iversen KK; Ostrowski SR; Bundgaard H; Frikke-Schmidt R; Garred P; Skjoedt MO
Front Immunol; 2021; 12():757197. PubMed ID: 34691078
[TBL] [Abstract][Full Text] [Related]
2. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B
Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620
[TBL] [Abstract][Full Text] [Related]
4. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
Elife; 2021 Aug; 10():. PubMed ID: 34435953
[TBL] [Abstract][Full Text] [Related]
5. Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies.
Alenquer M; Ferreira F; Lousa D; Valério M; Medina-Lopes M; Bergman ML; Gonçalves J; Demengeot J; Leite RB; Lilue J; Ning Z; Penha-Gonçalves C; Soares H; Soares CM; Amorim MJ
PLoS Pathog; 2021 Aug; 17(8):e1009772. PubMed ID: 34352039
[TBL] [Abstract][Full Text] [Related]
6. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
Wang Z; Schmidt F; Weisblum Y; Muecksch F; Barnes CO; Finkin S; Schaefer-Babajew D; Cipolla M; Gaebler C; Lieberman JA; Oliveira TY; Yang Z; Abernathy ME; Huey-Tubman KE; Hurley A; Turroja M; West KA; Gordon K; Millard KG; Ramos V; Da Silva J; Xu J; Colbert RA; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Gazumyan A; Caskey M; Bjorkman PJ; Casellas R; Hatziioannou T; Bieniasz PD; Nussenzweig MC
Nature; 2021 Apr; 592(7855):616-622. PubMed ID: 33567448
[TBL] [Abstract][Full Text] [Related]
7. Functional Antibodies Against SARS-CoV-2 Receptor Binding Domain Variants with Mutations N501Y or E484K in Human Milk from COVID-19-Vaccinated, -Recovered, and -Unvaccinated Women.
Demers-Mathieu V; Hakansson AP; Hall S; Lavangnananda S; Fels S; Medo E
Breastfeed Med; 2022 Feb; 17(2):163-172. PubMed ID: 34809492
[No Abstract] [Full Text] [Related]
8. Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants.
Laffeber C; de Koning K; Kanaar R; Lebbink JHG
J Mol Biol; 2021 Jul; 433(15):167058. PubMed ID: 34023401
[TBL] [Abstract][Full Text] [Related]
9. The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice.
Bayarri-Olmos R; Johnsen LB; Idorn M; Reinert LS; Rosbjerg A; Vang S; Hansen CB; Helgstrand C; Bjelke JR; Bak-Thomsen T; Paludan SR; Garred P; Skjoedt MO
Elife; 2021 Nov; 10():. PubMed ID: 34821555
[TBL] [Abstract][Full Text] [Related]
10. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK
EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2.
Amanat F; Thapa M; Lei T; Ahmed SMS; Adelsberg DC; Carreño JM; Strohmeier S; Schmitz AJ; Zafar S; Zhou JQ; Rijnink W; Alshammary H; Borcherding N; Reiche AG; Srivastava K; Sordillo EM; van Bakel H; ; Turner JS; Bajic G; Simon V; Ellebedy AH; Krammer F
Cell; 2021 Jul; 184(15):3936-3948.e10. PubMed ID: 34192529
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape.
Yang L; Li J; Guo S; Hou C; Liao C; Shi L; Ma X; Jiang S; Zheng B; Fang Y; Ye L; He X
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829998
[TBL] [Abstract][Full Text] [Related]
13. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.
Augusto G; Mohsen MO; Zinkhan S; Liu X; Vogel M; Bachmann MF
Allergy; 2022 Jan; 77(1):111-117. PubMed ID: 34453338
[TBL] [Abstract][Full Text] [Related]
14. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies.
Shah M; Woo HG
Front Immunol; 2021; 12():830527. PubMed ID: 35140714
[TBL] [Abstract][Full Text] [Related]
15. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
Zahradník J; Marciano S; Shemesh M; Zoler E; Harari D; Chiaravalli J; Meyer B; Rudich Y; Li C; Marton I; Dym O; Elad N; Lewis MG; Andersen H; Gagne M; Seder RA; Douek DC; Schreiber G
Nat Microbiol; 2021 Sep; 6(9):1188-1198. PubMed ID: 34400835
[TBL] [Abstract][Full Text] [Related]
17. Insights into SARS-CoV-2's Mutations for Evading Human Antibodies: Sacrifice and Survival.
Luan B; Huynh T
J Med Chem; 2022 Feb; 65(4):2820-2826. PubMed ID: 33834772
[TBL] [Abstract][Full Text] [Related]
18. Postvaccination SARS-COV-2 among Health Care Workers in New Jersey: A Genomic Epidemiological Study.
Mathema B; Chen L; Chow KF; Zhao Y; Zody MC; Mediavilla JR; Cunningham MH; Composto K; Lee A; Oschwald DM; Germer S; Fennessey S; Patel K; Wilson D; Cassell A; Pascual L; Ip A; Corvelo A; Dar S; Kramer Y; Maniatis T; Perlin DS; Kreiswirth BN
Microbiol Spectr; 2021 Dec; 9(3):e0188221. PubMed ID: 34787439
[TBL] [Abstract][Full Text] [Related]
19. Computational decomposition reveals reshaping of the SARS-CoV-2-ACE2 interface among viral variants expressing the N501Y mutation.
Socher E; Conrad M; Heger L; Paulsen F; Sticht H; Zunke F; Arnold P
J Cell Biochem; 2021 Dec; 122(12):1863-1872. PubMed ID: 34516024
[TBL] [Abstract][Full Text] [Related]
20. B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies.
Zhou H; Dcosta BM; Samanovic MI; Mulligan MJ; Landau NR; Tada T
mBio; 2021 Aug; 12(4):e0138621. PubMed ID: 34311587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
